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The purpose of the RAZOR (randomized open vs robotic
cystectomy) study is to compare open radical cystectomy
(ORC) vs robot-assisted RC (RARC), pelvic lymph node
dissection (PLND) and urinary diversion for oncological
outcomes, complications and health-related quality of
life (HRQL) measures with a primary endpoint of
2-year progression-free survival (PFS). RAZOR is a
multi-institutional, randomized, non-inferior, phase III trial
that will enrol at least 320 patients with T1–T4, N0–N1, M0
bladder cancer with ≈160 patients in both the RARC and ORC
arms at 15 participating institutions. Data will be collected
prospectively at each institution for cancer outcomes,
complications of surgery and HRQL measures, and then
submitted to trial data management services Cancer Research
and Biostatistics (CRAB) for ﬁnal analyses. To date, 306
patients have been randomized and accrual to the RAZOR
trial is expected to conclude in 2014. In this study, we report
the RAZOR trial experimental design, objectives, data safety,
and monitoring, and accrual update. The RAZOR trial is a
landmark study in urological oncology, randomizing T1–T4,
N0–N1, M0 patients with bladder cancer to ORC vs RARC,
PLND and urinary diversion. RAZOR is a multi-institutional,
non-inferiority trial evaluating cancer outcomes, surgical
complications and HRQL measures of ORC vs RARC with a
primary endpoint of 2-year PFS. Full data from the RAZOR
trial are not expected until 2016–2017.
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Introduction
In 2012, ≈74 000 patients were diagnosed with urinary bladder
cancer with nearly 15 000 estimated deaths from bladder cancer
in the USA alone [1]. Radical cystectomy (RC) with pelvic
lymphadenectomy (PLND) and urinary diversion is a standard
of care for both high-risk, non-muscle-invasive bladder cancer
and muscle-invasive disease [2,3]. This surgery is extremely
complex and associated with considerable postoperative
morbidity [4–6], with major and minor complications after
open RC (ORC) of ≈13% and 67%, respectively [4,5].
Robot-assisted RC (RARC) is a less invasive technique with RC
and PLND accomplished via a robot-assisted laparoscopic
approach [7]. After completion of the RC and PLND, urinary
diversion is performed by either extracorporeal or
intracorporeal techniques. Potential advantages of RARC from
small-volume, single-institution series are decreased estimated
blood loss (EBL), decreased blood transfusion rates, diminished
pain and opioid requirements, earlier time to oral intake,
shorter hospital stay, fewer wound complications, and expedited
perioperative and postoperative convalescence and recovery
[8–10]. From a cancer perspective, RARC does not appear to
compromise oncological outcomes deﬁned by surgical margin
status and number of pelvic lymph nodes removed in early
robotic series [8–10].
Nix et al. [11] conducted a small (41 patients) prospective,
randomized, single centre, trial of RARC vs ORC with a
primary endpoint of lymph node yield. Signiﬁcant diﬀerences
were noted in operating room time, EBL, time to ﬂatus and
bowel movement, as well as use of inpatient morphine
equivalents, without signiﬁcant diﬀerences in complications or
hospital stay. The mean number of lymph nodes removed was
19 (RARC) vs 18 (ORC), demonstrating non-inferiority.
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Parekh et al. [12] conducted a pilot, prospective randomized
trial evaluating perioperative outcomes and oncological
eﬃcacy of RARC vs ORC in 40 consecutive patients with
signiﬁcantly decreased EBL and trends toward decreased
length of stay of >5 days and fewer transfusions in the RARC
group. There were no signiﬁcant diﬀerences in positive
margins or number of lymph nodes removed for RARC
compared with ORC, although fewer lymph nodes were
recovered via the robotic approach.
Nonetheless, RARC is still associated with signiﬁcant
complications. Johar et al. [13] described complications
in 939 patients after RARC from the International Robotic
Cystectomy Consortium database, with complications
analysed and graded according to the Memorial
Sloan-Kettering Cancer Center system. In all, 41% and 48%
of patients had complications at ≤30 and ≤90 days of
surgery, respectively. Nearly 20% of patients had a grade ≥3
complication after RARC and 90-day mortality was 4.2%. Yuh
et al. [14] reported on 196 patients who underwent RARC,
extended PLND, and urinary diversion, with continent
diversions performed in 68% of cases. Complications at ≤90
days of surgery were deﬁned and categorised by the modiﬁed
Clavien system. In all, 80% of patients had a complication ≤90
days after surgery, and 35% had a major complication, with
90-day mortality of 4.1%. Thus, postoperative complications
and morbidity after RARC are considerable but generally
similar to contemporary ORC series.
RARC for bladder cancer has the potential for improving
perioperative morbidity compared with ORC without
compromise of oncological eﬃcacy. Unfortunately, the vast
majority of studies to date are retrospective with signiﬁcant
inherent selection bias. High levels of clinical evidence for
the beneﬁts of RARC are absent, and current experiences
represent case series with limited comparisons to historical
controls, or small, single-institution randomized clinical trials
at best. Comparative results of RARC vs ORC clearly need
validation in larger, multicentre, randomized, prospective
clinical trials and this is certainly the goal of the RAZOR
(randomized open vs robotic cystectomy) trial.
RAZOR Experimental Design
This multi-institutional, randomized, prospective,
non-inferiority, phase III trial will enrol at least 320 patients
with ≈160 in both the RARC and ORC arms at 15
participating institutions (Table 1). Thus far, 306 patients have
been randomized to the RAZOR study from 19 August 2011
to the 19 December 2013: an average of ≈11 patients accrued
per month, with expected completion of patient accrual in
2014. This study aims to determine whether RARC for
treatment of bladder cancer provides non-inferior oncological
control vs traditional ORC with a primary endpoint of 2-year
progression-free survival (PFS). A multi-institutional approach
with patients randomized to either approach having surgery
performed by experienced surgeons should minimise both
institutional and surgeon biases.
Patient Inclusion Criteria
Patients must have biopsy conﬁrmed bladder cancer; clinical
stages T1–T4, N0–N1, M0, or carcinoma in situ refractory to
intravesical therapies. Review of the oﬃcial pathology report
at participating institutions is mandatory but central
pathological review is not required.
Patient Exclusion Criteria
Inability to give informed consent, age of <18 or >99 years,
and pregnancy are absolute exclusion criteria. In addition, at
the discretion of the treating surgeon, previous major
abdominal or pelvic surgical procedures precluding a safe
robotic approach or any pre-existing condition, e.g. severe
chronic obstructive pulmonary disease, precluding safe
initiation or maintenance of pneumoperitoneum during
surgery are also exclusion factors.
Research Procedures (Tables 2,3)
Any patient deemed a candidate for RARC will be oﬀered
participation in the study in attempts to eliminate selection
bias. Eligible, consented patients are randomized to RARC or
ORC no >60 days before surgery using a dynamic balancing
algorithm on type of diversion, within each institution as a
block via a web-based patient enrolment and randomization
system through the data management services of Cancer
Research and Biostatistics (CRAB). Surgeons performing
RARC and/or ORC must have performed ≥10 each over the 1
year prior to approval as a study site.Within each study site,
the open and robotic surgeon(s) could be more than one
individual. All urinary diversions are extracorporeal with
speciﬁc type selected by mutual agreement of the patient and
Table 1 Accrual of patients to date at the 15 participating institutions.
Institution Accrual, n
Mayo Clinic, Arizona 50
Stanford University 40
University of Texas – San Antonio 34
University of Michigan 30
University of North Carolina 30
Mayo Clinic, Minnesota 21
University of Minnesota 20
University of Chicago 17
University of Virginia 13
University of Miami 13
Ohio State University 12
Vanderbilt University 9
University of California – Irvine 8
Loyola University – Chicago 8
Brigham and Women’s Hospital 1
Total 306
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surgeon. The extent of PLND (standard vs extended template)
is also determined by the surgeon but at a minimum includes
external iliac, obturator, and hypogastric regions. Standard and
extended surgical templates were implemented for the study
and adherence to these templates assessed by submission of a
‘Surgeon’s Intraoperative Data Form’ for all cases to CRAB.
Objectives of the RAZOR Trial
Oncological
The primary endpoint of the RAZOR trial is 2-year PFS,
with stratiﬁcation factors including type of urinary diversion,
clinical stage and neoadjuvant chemotherapy. As a
non-inferiority comparison, the study will test whether
RARC is (at worst) inferior to ORC by a small pre-deﬁned
margin. For statistical power and signiﬁcance, the margin for
this trial is 15%, meaning RARC would be considered
inferior if 2-year PFS is >15% lower than ORC. A total of
288 evaluable patients (144 patients per arm) yields 80%
power and a two-sided signiﬁcance level (α) of 5% to
correctly reject the null-hypothesis of unacceptable
inferiority of RARC. These calculations are based on
assumptions that 2-year PFS in the patients receiving ORC
is roughly 70% [2] and the rate of 2-year progression is
binomially distributed. Concerning analysis of the primary
endpoint, a one-sided Mantel–Haenszel test with half
the α (0.025) will be used for testing the primary
non-inferiority hypothesis comparing 2-year PFS between
treatment arms. The study uses a centralised dynamic
allocation procedure to allocate equal numbers of patients to
each treatment arm and balance marginal distribution of
stratiﬁcation factors between treatment arms. Participation
was anticipated at 15 sites with estimated overall accrual of
110 eligible patients per year. Assuming a maximum
drop-out rate of 10%, a total of at least 320 patients (160 in
each arm) will be accrued over ≈3 years and followed for at
least 2 years for disease progression. Based on accrual
estimates, after 3 years of accrual and 2 additional years of
follow-up, 65% of patients should have follow-up data
available to evaluate PFS at 3 years. Thus, study duration is
expected to be ≈5 years.
Table 3 Data submission procedures. Data must be submitted according to the following schedule.
1. Perform randomization and obtain subject identiﬁcation number: Randomization Form.
2. Within 1 week after enrolment:
Medical History Form
Surgical History Form
Findings at TURBT Form
Haemoglobin, BMP, and Serum Albumin Form
Screening Physical Examination and Vital Signs Form
Baseline Disease Assessment Form
Baseline FACT-VCI HRQL Questionnaire
Baseline SF-8 HRQL Questionnaire
Baseline ADL HRQL Questionnaire
Baseline IADL HRQL Questionnaire
Baseline Hand Grip Strength Form
Baseline Timed Up and GoWalking Test Form
3. Within 1 week of surgery: Surgeon’s Intraoperative Data Form
4. Within 1 week of discharge for surgical hospitalisation:
Hospital Discharge Visit: OR and Hospital Costs Reporting Form
Surgeon’s Postoperative Data Form
5. Within 1 week of each post-surgery laboratory assessment:
Haemoglobin, BMP, and Serum Albumin Form
6. Within 1 week of each scheduled ADL, IADL, and HRQL assessment:
FACT-VCI HRQL Questionnaire
SF-8 HRQL Questionnaire
ADL HRQL Questionnaire
IADL HRQL Questionnaire
Hand Grip Strength Form
Timed Up and GoWalking Test Form
7. Within 2 weeks of each scheduled disease assessment/imaging examination:
Post-surgical Disease Assessment Form
8. Within 4–6 weeks after surgery:
Cystectomy Pathology Form
9. Within 1 week following the 90-day postoperative period:
Surgeon’s 90-day Data Form
10. Within 1 week of the 6-, 12-, 24-, and 36 months postoperative assessments (respectively):
Post-surgical Disease Assessment Form
Haematology Form
Serum Chemistry Form
BMP, basic metabolic panel.
The RAZOR trial
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Of note, in superiority trials the intent-to-treat (ITT)
population is widely accepted for analysis of the primary
endpoint as it gives the most conservative result. In contrast,
for non-inferiority trials the inclusion of ineligible or
untreated patients, or lack of adherence to the assigned
treatment is expected to increase background noise of the
study and make the treatment arms look more alike, and thus
the overall results of the study less conservative. RAZOR
therefore uses the per-protocol (PP) population for analysis of
the primary endpoint, as well as all eﬃcacy and health-related
quality of life (HRQL) endpoints. The PP population is a
subset of the ITT population and includes all patients who
met inclusion/exclusion criteria and received surgery. The ITT
population includes all patients randomized to the trial, and a
sensitivity analysis of the primary endpoint using the ITT
population will also be performed. Trial design and analysis
are based on Southwest Oncology Group (SWOG) standards
for non-inferiority trials.
Patients will be followed from the date of surgery to the date
of ﬁrst documentation of progression of bladder cancer or
death from any cause. Imaging of the chest, abdomen and
pelvis will be performed at baseline and then again at 12, 24
and 36 months to assess for disease recurrence (Table 2).
Acceptable modalities include chest X-ray, CT imaging of the
chest, abdomen and pelvis, as well as MRI of the abdomen and
pelvis, given patient factors and surgeon discretion. Although
follow-up history, physical examination, laboratory and
surveillance imaging schedules are uniform for the RAZOR
trial (Table 2), some authors advocate a more individualised,
risk-based surveillance strategy based on pathology at the
time of RC [15]. Patients known to be alive and progression
free are censored at date of last contact. Progression is
determined using Response Evaluation Criteria In Solid
Tumors (RECIST) 1.1 criteria based on either radiographic or
pathological evidence of disease progression, or death from
disease. Any documented recurrence is considered
progression. All patients will be followed for at least 2 years
and an estimated 65% followed for 3 years. Overall survival
(OS) is deﬁned from date of surgery to date of death from
any cause. Patients last known to be alive are censored at
date of last contact. PFS and OS will be evaluated using the
Kaplan–Meier method and comparisons between arms using
the stratiﬁed log-rank test.
Laboratory
Serum haemoglobin and comprehensive metabolic panel
(CMP) are part of routine preoperative evaluation and
postoperative follow-up in patients undergoing RC and
urinary diversion and are thus determined at baseline and in
the postoperative period at 4–6 weeks, and at 3, 6, 12, 24, and
36 months. Linear mixed eﬀects are used to compare blood
level parameters and changes over time between the two
treatment groups.
HRQL
HRQL outcomes are measured at baseline and postoperatively
at 3 and 6 months using the Functional Assessment of Cancer
Therapy–Vanderbilt Cystectomy Index (FACT-VCI) as well as
the Short Form 8 (SF-8) questionnaires. Simple descriptive
statistics, including mean and standard deviation (SD) are used
to summarise FACT-VCI and SF-8 scores at each time point
for each treatment group. A multivariate linear mixed eﬀects
model is ﬁtted to each score in this repeated measures
design. The main eﬀect is visit (at baseline, 3 and 6 months)
and treated as a categorical variable to accommodate for
non-linear trends. If time corresponding to a particular visit
diﬀers signiﬁcantly between patients, a variable representing
deviation from the visit-speciﬁc mean time is added to the
model. Standard diagnostic tools are used to assess model ﬁt.
Several patient-reported and performance-related measures of
functional independence are analysed as part of the RAZOR
trial. Activities of Daily Living (ADL) and Instrumental
ADL (IADL) scores are determined both at baseline and
postoperatively at 4–6 weeks, and at 3 and 6 months. Hand
Grip Strength Test and Timed Up and GoWalking Test
outcomes are evaluated at baseline and postoperatively at 4–6
weeks, and at 3 and 6 months. Hand Grip Strength at 3
months after surgery is measured as a surrogate for recovery
after surgery. Previous reports suggest only 39% of patients
recovered at 3 months after a major abdominal surgery as
measured by Hand Grip Strength [16].
RAZOR compares the proportion of patients recovered as
measured by Hand Grip Strength between the two treatment
arms.We hypothesise 20% more patients will have recovered 3
months after surgery in the RARC arm compared with the
ORC arm. A total of 288 patients yield 91% power and a
one-sided signiﬁcance level of 0.025 to detect a diﬀerence
between arms of at least 20%. These calculations are based on
assumptions that Hand Grip Strength at 3 months is
binomially distributed.
Operative
It is estimated nodal templates will be equivalent for RARC
and ORC with minimal standard template PLND including all
potential lymph node-bearing tissue with the lateral limit the
genitofemoral nerve, distally Cooper’s ligament to include
Cloquet’s node, proximally the crossing of the ureter over the
common iliac vessels, medially the bladder including tissue
medial to the hypogastric artery, posteriorly the ﬂoor of the
obturator fossa with circumferential mobilisation of the
external iliac artery and vein oﬀ the pelvic sidewall. Surrogates
of surgical quality are compared by evaluating surgical margin
status and number of lymph nodes removed. Surgical soft
tissue margin as a measure for local cancer control is
measured as positive or negative for each patient and
Review
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compared between arms using a Fisher’s exact test. The
number of nodes resected in each arm is compared using
a t-test.
Pathological
The RC specimen (with or without uterus, ovaries, or vaginal
cuﬀ in females and prostate in males) is submitted en bloc,
processed and assessed in a standardised fashion at all
participating institutions for margin status along with
histology, tumour size, stage, grade and presence/absence of
lymphovascular invasion. At a minimum, lymph nodes are
submitted in two separate packets labelled left and right pelvic.
All regions may be submitted in smaller packets (e.g. external
iliac, obturator, internal iliac) at surgeon discretion.
Pathological data is obtained from pathology reports after
surgery with particular emphasis on surgical margin status,
total number of lymph nodes removed and their involvement
with cancer, as well as pathological stage of the tumour. A
standardised form is used to collect all information pertaining
to specimen processing and staging by the participating
institutions, and the standardised ‘Cystectomy Pathology
Form’ submitted to CRAB with a copy of the pathology report
available in patients’ clinical records.
Perioperative
Perioperative measures, e.g. EBL, blood transfusion rates,
intraoperative ﬂuid requirements, operative time,
postoperative length of hospital stay and analgesic
requirement, are prospectively recorded during surgery and
the postoperative hospital stay using anaesthesia, operative,
nursing and inpatient medical records by a research
coordinator. All medications are converted to morphine
equivalents using the online calculator, The Clinician’s
Ultimate Reference found at http://www.globalrph.com/
narcoticonv.htm.
RAZOR will determine whether RARC is superior to ORC in
terms of blood loss by comparing EBL between groups. A total
of 288 patients yield 90% power and a one-sided signiﬁcance
level of 0.025 to detect a diﬀerence of blood loss between the
two treatment groups of 20%. These calculations are based on
assumptions that blood loss is normally distributed, and the
mean (SD) EBL for ORC is 575 (300) mL. RAZOR will also
determine whether RARC is superior to ORC in terms of
transfusion rates. The transfusion rate for ORC is estimated at
75%. A total of 288 patients yield 92% power and a one-sided
signiﬁcance level of 0.025 to detect a diﬀerence in transfusion
rates between arms of at least 20%. These calculations are
based on the assumption that transfusion rate is binomially
distributed.
Length of hospital stay is used as a surrogate for recovery after
surgery. RAZOR will determine whether RARC is superior to
ORC in terms of length of hospital stay. It is estimated all
patients receiving ORC stay in the hospital for >5 days while
67% of patients undergoing RARC stay in the hospital for >5
days. A total of, 288 patients yield 97% power and a one-sided
signiﬁcance level of 0.025 to detect a diﬀerence in the
percentage of patients requiring a hospital stay beyond 5 days
between arms of at least 20%. These calculations are based on
the assumption that the percentage of patients requiring a
>5-day hospital stay is binomially distributed.
Morbidity
Perioperative morbidity and mortality are evaluated using
the modiﬁed Clavien grading system for complications by
prospectively recording intraoperative and postoperative
complications until discharge and by patient interview during
the post-discharge period until 90 days after surgery.
Cost
RAZOR compares ﬁxed and variable costs associated with
RARC and ORC operating room and hospital components.
Fixed and variable operating room costs are assessed using
amortised cost of the robot per case, amortised cost of robot
maintenance per case, costs of dispensable equipment, cost of
operating room personnel and anaesthesia resources per time.
Fixed and variable hospital costs are obtained based on length
of stay. Cost data is collected from each participating centre
then stored and analysed by CRAB.We hypothesise that
costs associated with RARC will be no more than 5% greater
than ORC.
Data Safety and Monitoring (Table 4)
A Data and Safety Monitoring Committee (DSMC) will
oversee the conduct of the study and consist of ﬁve voting,
independent members: one surgeon, one medical oncologist,
one Certiﬁed Clinical Research Associate (CCRA)/Registered
Nurse (RN), one biostatistician, and one lay person.
Non-voting members include support staﬀ from CRAB (who
will prepare the DSMC reports), and project faculty (Principal
Investigators) as appropriate. DSMC members receive
database summaries from CRAB, including adverse events
(AEs) and post-surgical complications reports, serious AE
(SAE) summaries, and other pertinent patient/treatment
summary information. Meetings occur every 6 months via
Table 4 AE submission procedures. Data about AEs must be submitted
according to the following schedule.
1. Within 1 week of each scheduled AEs evaluation until AEs have resolved:
Surgical Complications-Adverse Events Form
2. Within 7 days or 48 h if life-threatening for each SAE:
Flag as ‘SAE’ on the Surgical Complications-Adverse Events Form
3. Within 2 weeks of knowledge of death, if death occurs before the end of the study:
Death Report Form
The RAZOR trial
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teleconference. The DSMC is responsible for decisions about
possible termination and/or early reporting of the study.
Subject data is examined at each follow-up visit and subjects
queried for AEs deﬁned as complications related to RARC,
ORC and/or study procedures. An AE or complication is the
appearance of undesirable sign(s), symptom(s), or medical
condition(s) occurring after a participant signs informed
consent and considered to be related to RARC, ORC and/or
study procedures. A SAE is any untoward medical occurrence
that is fatal or life-threatening, requires hospitalisation
or prolongation of existing hospitalisation, results in
disability/incapacity, or is medically signiﬁcant and may
jeopardise the patient or may require medical or surgical
intervention to prevent one of the outcomes listed above. All
AEs or complications will be graded for severity according to
the modiﬁed Clavien grading system. All AEs will be reported
to the Institutional Review Board (IRB) at the time of annual
review and to the DSMC as described below.
Each investigator must assess the relationship between any
study-related procedure and occurrence of each SAE. The
investigator uses clinical judgment to determine the potential
relationship. Alternative causes, such as natural history of
underlying diseases, concomitant therapy, other risk factors,
and temporal relationship of the event to any study-related
procedure is considered and investigated. The investigator
may change his/her opinion of causality in light of follow-up
information and amend the SAE case report form and
report accordingly. SAEs meeting the IRB deﬁnition of
‘Unanticipated Problems Involving Risk to Subjects or Others’
(UPIRSO) are reported to the IRB within 7 days, and within
48 h if life-threatening or fatal. All SAEs are also summarised
and communicated across sites via posting to the secure study
website at https://prodq.crab.org/Parekh/Login.aspx. Data are
reviewed on a biweekly basis by investigators to ensure quality
control and safety. During the study, when there is a safety
evaluation, the investigator and/or research staﬀ are
responsible for detecting, documenting and reporting AEs or
SAEs to the local IRB.
Potential Limitations of the RAZOR Trial
Randomized surgical clinical trials are challenging for myriad
reasons, and the RAZOR study is not immune to many of
these challenges. Firstly, not all surgeons are created equal.
Surgical talent and experience vary widely. However,
Birkmeyer et al. [17,18] studied the relationship of surgeon
and hospital volumes on mortality after RC and urinary
diversion, and found both surgeon and hospital volumes were
inversely related to perioperative mortality. All surgeons in the
RAZOR trial would be categorised as high-volume surgeons
from high-volume hospitals in these studies, thus minimising
surgeon variability. Another potential limitation of the
RAZOR trial is the learning curve of RARC and possibly
comparing an established technique to a novel technique
with many surgeons still on the learning curve. Surgeons
performing RARC and/or ORC in the RAZOR study must
have performed ≥10 each over the 1 year prior to approval as
a study site in an eﬀort to minimise the inﬂuence of the
learning curve. In addition, if RARC is non-inferior to ORC
for cancer control, the outcomes of RARC should only
improve with more widespread dissemination of technique.
Finally, the true impact of RARC on HRQL outcomes
may be underestimated in the RAZOR trial due to use of
extracorporeal urinary diversion. Although the primary
endpoint of the RAZOR trial is oncological with HRQL a
secondary measure, the full HRQL inﬂuence of RARC may
perhaps only be realised with intracorporeal urinary diversion.
Conclusions
The RAZOR study is a landmark multi-institutional,
prospective, non-inferiority trial evaluating oncological
outcomes, surgical complications, and HRQL measures of
ORC vs RARC in patients with T1–T4, N0–N1, M0 bladder
cancer with a primary endpoint of 2-year PFS. Thus far, 306
patients have been randomized to the RAZOR study from 19
August 2011 to 19 December 2013: an average of ≈11 patients
accrued per month, with expected completion of patient
accrual in 2014. Full data from the RAZOR trial are not
anticipated until 2016–2017 but should provide much needed
level 1 data about the comparative eﬃcacy of RARC vs ORC
in terms of both cancer control and HRQL.
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